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Abstract 
Objectives: To report reliable short and long-term survival rate estimates for people with a 
diagnosis of heart failure and assess trends over time by year of diagnosis, hospitalisation 
and socioeconomic group. 
Design: Population-based cohort study. 
Setting: Primary Care, United Kingdom. 
Population: Primary care data from 55,959 patients over age 45 years with a new diagnosis 
of heart failure, and 278, 679 age-sex matched controls, in the Clinical Practice Research 
Datalink between 1st January 2000 and 31st December 2017 were linked to inpatient 
Hospital Episode Statistics and the Office for National Statistics civil death registry.  
Main outcome measures: Survival rates at one, five and ten-years, and cause of death, for 
people with and without heart failure. Temporal trends in survival by year of diagnosis, 
hospitalisation and socioeconomic quintile.  
Results: Overall, one, five and ten-year survival rates increased by 6.6% (74.2% in 2000 to 
80.8% in 2016), 7.2% (41.0% in 2000 to 48.2% in 2012) and 6.3% (19.8% in 2000 to 26.2% in 
2007) respectively. There were 30,906 deaths in the heart failure group over the study 
period. Heart failure was listed on the death certificate in 13.093 (42.4%) of these patients, 
including 2,237 (7.2%) where it was the primary cause of death. Improvement in survival 
was greater for those not requiring hospitalisation around the time of diagnosis (median 
difference 2.4 years; 5.3 vs 2.9 years, p<0.0001). There was a deprivation gap in median 
survival of 2.4 years between the least and most deprived individuals (11.1 vs 8.7 years, 
p<0.0001). 
Conclusions: Survival following a diagnosis of heart failure has shown only modest 
improvement in the 21st Century lagging behind other malignant conditions. New strategies 
to achieve timely diagnosis and treatment initiation in primary care for all socioeconomic 
groups should be a priority for future research and policy. 
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Introduction 
Heart failure (HF) is a common, costly but manageable clinical syndrome.1,2 A rise in 
cardiovascular risk factors, improved survival from ischaemic heart disease and population 
ageing have contributed to a sustained increase in prevalence.3 Recent analysis of United 
Kingdom (UK) primary care data found the absolute number of people living with HF 
increased by 23% between 2002 and 2014 from 750,125 to 920,616 (1.4% of the 
population).4 The global economic cost of HF is estimated at $108 billion per year, due to 
direct costs to healthcare systems and indirect costs to society through loss of productivity, 
with the greatest expenditure in the last three months of life.5,6 Pharmacological therapies, 
devices and exercise-based rehabilitation can improve outcomes for patients, particularly in 
HF with reduced ejection fraction, but diagnosis is crucial to allow timely initiation of 
evidence-based therapies.   
For any long-term condition, reliable and contemporary survival estimates are important at 
population level, to monitor trends in prognosis and to commission appropriate services. At 
a patient level they allow informed discussions and shared decision making about treatment 
options and advanced care planning.7 Previous prognostic studies in HF have used data from 
hospital inpatients or screening studies to report survival. People with established HF 
requiring hospitalisation for acute decompensation have high mortality rates with up to one 
in six patients dying during admission or within 30 days post-discharge.8,9 Survival for 
screen-detected HF is more favourable with around half of all study participants alive at five 
years.10,11 Studies of people diagnosed with HF in a routine community setting are limited 
and inconsistent, with conflicting findings for trends in survival over time.12–14 Analysis from 
primary care records in the The Health Improvement Network showed no change in survival 
following a diagnosis of HF between 1998 and 2012 which was alarming to the HF 
community and the wider public. Contemporary data are needed to establish if outlook has 
improved in recent years, and explore factors associated with worse outcome. 
Charities, cardiology organisations and government bodies have produced regional and 
country-specific guidelines to inform evidence-based practice, with the aim of improving 
patient outcomes, but uptake is not universal.15,16 The National Heart Foundation of 
Australia and the National Institute for Health and Care Excellence in England have recently 
updated their HF guidelines with new recommendations including a focus on collaboration 
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between primary and secondary care.17,18 Within healthcare systems, HF has also not 
received the same strategic focus and funding resource as other long-term conditions.  
The aim of this study was to use primary care records, linked to inpatient and civil death 
registry data, to report the short, mid and long-term survival of people with HF in the 
community and examine trends over time by year of diagnosis, hospitalisation around time 
of diagnosis and socioeconomic group. 
Methods 
Design and setting 
An open matched retrospective population-based cohort study was carried out using data 
from the Clinical Practice Research Datalink (CPRD) for the period between 1st January 2000 
and 31st December 2017. CPRD is a primary care database containing electronic patient 
records from over 700 general practices and is representative of the UK population.19 At 
each consultation, symptoms or diagnoses are entered using a clinical coding system. 
Clinical observations, laboratory tests, prescriptions and demographic details also form part 
of the electronic record. 
Practices that contributed at least one year of clinical data were included in the study. Data 
quality measures included the up-to-standard date (which incorporates death reporting) 
and the patient acceptable flag. CPRD classes patient records as ‘acceptable’ for research 
purposes. This is a simple quality check to ensure that the records used for research projects 
are as accurate and reliable as possible. CPRD data were linked to the Office for National 
Statistics (ONS) civil death registry to provide the date and cause of death. The data were 
also linked to inpatient Hospital Episode Statistics (HES) to determine hospitalisation around 
the time of diagnosis and the Index of Multiple Deprivation (IMD) to determine 
socioeconomic status. IMD is calculated for the postal district of the individual’s place of 
residence and combines information from seven domains (income, employment, education 
and training, health and disability, crime, barriers to housing and services, and living 
environment). The validity and reliability of the IMD as a measure of socioeconomic status 
has previously been reported. 
The full study protocol was approved by the Independent Scientific Advisory Committee 
(ISAC) to the Medicine and Healthcare products Regulatory Authority (protocol number 
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18_061R). Ethical approval for observational research using the CPRD with approval from 
ISAC has been granted by a National Research Ethics Service committee (05/MRE04/87).  
Study population 
The cohort was extracted from CPRD and included acceptable patient records of persons 
aged 45 years and over, registered at an up-to-standard practice for at least 12 months 
between 1st January 2000 and 31st December 2017. Entry criteria to the cohort were a 
diagnostic code of HF in the patient primary care record and eligibility for HES and ONS 
linkage.  
Patients entered the cohort on the latest of the following dates: 1st January 2000, date of 
45th birthday, patient registration date plus 12 months, practice up to standard date plus 12 
months. Patients with a diagnosis of HF occurring before this date were excluded. Patients 
exited the cohort on the earliest of the following dates: 31st December 2017, patient 
transferred out date, date of death, last date of practice data collection, last date of 
available linked data. 
Demographic variables including age, sex, ethnicity, patient level deprivation quintile (IMD), 
cardiovascular risk factors and co-morbidities were extracted for each participant. 
Cardiovascular risk factors (smoking, blood pressure, cholesterol, body mass index (BMI)) 
were the most recent recorded prior to the index date. Cardiovascular co-morbidities 
(angina, myocardial infarction (MI), ischaemic heart disease, diabetes, hypertension, stroke, 
atrial fibrillation, valve disease), were defined by the presence of a clinical code at any time 
prior to the index date. 
Case definition 
People with a new diagnosis of HF in their primary care record were HF cases. The NHS 
Clinical Terminology Browser, Quality and Outcomes Framework guideline and International 
Classification of Diseases version 10 were used to generate a comprehensive list of terms 
used to code for a diagnosis of HF (online supplementary material).  
In CPRD, we identified first diagnosis of HF as the earliest recorded diagnostic code in the GP 
record. The index date (from which time to death was measured) was the first date of a 
recorded HF code in the primary care record within the study period. Cases were matched 
 6 
by age (+/- 5 years) and sex with up to five comparators registered in the same practice on 
the index date without a diagnosis of HF on that date (but could become a case later). 
Database linkage 
Linked data were supplied directly by CPRD. The process they use is a deterministic 
matching algorithm, matching exactly on NHS number and an exact match on at least one of 
other date of birth, sex and postcode. More than 97% of HES records and 98% of ONS death 
records are successfully matched in this way. 
Linked HES data was used to identify people admitted to hospital within 3 months of 
diagnosis (inpatient clinical code of HF and/or inpatient echocardiography report). This 3-
month period before or after the HF diagnosis was entered in the primary care record was 
chosen to allow time for flow of information between hospitals and practices. 
Cause of death is determined by ONS according to the information provided on the death 
certificate by the examining physician and is used in National Statistics in the UK, so is likely 
to be the most accurate data available. 
Outcomes 
The primary outcome measure was death (all-cause mortality). The date and cause of death 
were taken from ONS mortality data. Secondary outcomes, reported descriptively, included 
primary cause of death, death due to HF (at any position in the cause of death hierarchy), 
and death due to arrhythmias (ICD-9 code 427 and 10 codes I47-I49).  
Statistical analysis 
The numbers of HF cases were calculated, and baseline socioeconomic demographics 
presented for each group. Survival rates at one, five, ten and 15-years for HF cases and 
matched comparators were calculated for men and women, and by each 10-year age band 
over the age of 45. To investigate trends in mortality over time, survival was determined at 
one, five and ten years by year of diagnosis and by hospitalisation around the time of 
diagnosis. Linear trends in survival over time were investigated by fitting weighted linear 
regression of the survival rate on the year of diagnosis in which the weights were inversely 
proportional to the variance of the survival rate. To examine for socioeconomic inequalities, 
median survival for both least and most deprived IMD quintiles were compared by year. We 
computed the difference in survival rates between the earliest and most recent years of 
diagnosis, and calculated and 95% confidence intervals (CI) using the normal distribution. To 
Comment [CT6]: Add ref 
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adjust for any changes in the age/sex structure of the HF population over time, additional 
sensitivity analysis was carried out where survival rates were directly standardised by age 
and sex to the 2000 population. 
Kaplan-Meier curves and log rank tests were used to compare survival in people with and 
without HF and by sex, age and IMD quintile. Cox proportional hazards regression analyses 
assessed the overall effect of HF on survival, adjusting for potential confounders. To 
preserve the matched study design, the initial adjustment for age, sex, practice and time of 
diagnosis was performed by stratifying on matched set; further adjustment allowed for IMD 
quintile, ethnicity and cardiovascular (CV) risk factors where CV risk factors include lifestyle 
modifiable risk factors (BMI, smoking status, systolic and diastolic blood pressure, total 
cholesterol) and medical history (angina, MI, ischaemic heart disease (IHD), diabetes, 
hypertension, stroke, atrial fibrillation, valve disease). The proportional hazards assumption 
was tested by plotting Schoenfeld residuals over time. No clear trends over time were 
evident for any of the covariates in the model. 
There was substantial missing data for cholesterol and BMI and comparison of the 
characteristics of those with and without missing data suggested the data were not missing 
at random. Multiple imputation was therefore considered inappropriate and an alternative 
approach undertaken where continuous variables were categorised and unrecorded data 
represented by an additional missing category. Complete case analysis was undertaken as 
sensitivity analyses, with and without cholesterol and BMI as covariates. 
Statistical analysis was carried out using R (version 3.5.0) using ‘survival’ and ‘survminer’ 
packages.20–22 
Patient and public involvement 
We are grateful to our two patient representatives who both have HF and informed the 
research question and design for this study. They both initially found ‘heart failure’ a 
frightening term which suggested an imminent demise and were surprised to find it was a 
long-term condition which they would learn to live with. They felt that clinical staff 
inadequately covered the issue of survival following a diagnosis, and that they would ‘like 
doctors to have the facts’ as the provision of prognostic information given to them had been 
very limited. 
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Results 
A total of 385 CPRD practices contributed data, linked to both HES and ONS, between 1st 
January 2000 and 31st December 2017. Around 58% of practices within CPRD have linkage to 
HES data but remain representative of the UK population. Practices were also not included if 
they did not report data for the study period or had no eligible patients. There were 
2,456,338 patients aged 45 years and over registered for at least one year in the study 
period and eligible for linkage: 55,959 incident HF cases were identified and matched to 
278,679 controls. In the HF group, 24,125 people (43.1%) were hospitalised around the time 
of diagnosis overall The percentage of patients requiring hospitalisation around the time of 
diagnosis increased between 2000 and 2007, then remained stable from 2008 (see flow 
chart in online supplementary material). 
The baseline characteristics of people with HF, matched comparators and by hospitalisation 
around time of diagnosis and socioeconomic status are shown in Table 1. The average age at 
diagnosis was 77.1 (SD 10.6) years overall and did not change over the 18-year period. 
Women were on average almost five years older at diagnosis than men (79.6 years vs 74.8 
years). The proportion of people with HF admitted to hospital around the time of diagnosis 
increased from 28.9% in 2000 to 51.8% in 2010 then remained stable. Women, older people 
and those in the most deprived quintile were hospitalised more often around the time of 
diagnosis. Cardiovascular co-morbidity was common in the HF group overall but did not vary 
between hospitalisation and deprivation quintile groups. Average blood pressure was lower 
in the HF than the no HF group (systolic 137.5mmHg vs 139.6mmHg, diastolic 76.9mmHg vs 
77.6mmHg), likely to reflect initiation of diuretics, and other HF medication, around the time 
of diagnosis. Hypertension is a major risk factor for HF and a history of hypertension was 
more common in the HF group (57.7% vs 46.9%).
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Table 1: Baseline characteristics of people with heart failure and matched comparators 
 Cohort 
Characteristic 
Heart Failure No Heart Failure 
 
n % n % 
Overall, n (%) 55,959 (100) 278,679 (100) 
Sex, n (%)     
Male 29,234 (52.2) 145,552 (52.2) 
Female 26,725 (47.8) 133,127 (47.8) 
Age, mean (SD) 77.08 (10.6) 76.08 (10.4) 
Age category, n (%)     
45-54 1,938 (3.5) 11,056 (4.0) 
55-64 5,426 (9.7) 29,124 (10.5) 
65-74 12,485 (22.3) 67,851 (24.3) 
75-84 21,534 (38.5) 110,015 (39.5) 
85-94 13,453 (24.0) 57065 (20.5) 
95+ 1,123 (2.0) 3,568 (1.3) 
Ethnic group, n (%)     
White 44,143 (78.9) 204,936 (73.5) 
Non-white 1,497 (2.7) 6,516 (2.3) 
Mixed 6,585 (11.8) 38,114 (13.7) 
Missing 3,734 (6.7) 29,113 (10.4) 
Index of multiple 
deprivation (quintile)     
1 (least deprived) 10,854 (19.4) 60,020 (21.5) 
2 12,954 (23.1) 68,200 (24.5) 
3 11,947 (21.3) 58,956 (21.2) 
4 11,707 (20.9) 53,778 (19.3) 
5 (most deprived) 8,447 (15.1) 37,450 (13.4) 
Missing 50 (0.1) 75 (0.1) 
Smoking status, n (%)     
Never 21,252 (38.0) 123,460 (44.3) 
Former 7,094 (12.7) 31,494 (11.3) 
Current 24507 (43.8) 100,719 (36.1) 
Missing 3,106 (5.6) 23,006 (8.3) 
SBP, n (%)     
Mean (SD) (mmHg) 137.54 (21) 139.59 (18.0) 
Missing 1,272 (2.3) 14,367 (5.2) 
DBP, n (%)     
Mean(SD) (mmHg) 76.89 (11.6) 77.64 (10.0) 
Missing 1,272 (2.3) 14,367 (5.2) 
Total cholesterol, n (%)     
Mean(SD)(mmol/L) 4.69 (3.6) 5.03 (2.5) 
Missing 15,478 (27.7) 104,041 (37.3) 
BMI, n (%)     
Mean(SD)(kg/m2) 27.93 (6.1) 26.53 (4.8) 
Missing 8,428 (15.1) 50,110 (18) 
Medical History     
  AF, n (%) 14,629 (26.1) 20,910 (7.5) 
  Angina, n (%) 11,965 (21.4) 29,508 (10.6) 
  Diabetes, n (%) 13,104 (23.4) 38,824 (13.9) 
  Hypertension n (%) 32,316 (57.7) 130,669 (46.9) 
  IHD, n (%) 14,606 (26.1) 31,517 (11.3) 
  MI, n (%) 11,296 (20.2) 17,537 (6.3) 
  Stroke, n (%) 6,271 (11.2) 19,409 (7.0) 
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  VHD, n (%) 4,154 (7.4) 6,165 (2.2) 
  Other CVD, n (%) 13,757 (24.6) 34,578 (12.4) 
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Abbreviations: AF: Atrial Fibrillation; BMI: Body Mass Index; DBP: Diastolic Blood Pressure; HT: Hypertension; 
IHD: Ischaemic Heart Disease; MI: Myocardial Infarction; SBP: Systolic Blood Pressure; VHD: Valvular Heart 
Disease; CVD: Cardiovascular disease;. 
 12 
Cause of death 
The cause of death for HF cases and comparators are shown in Table 2. There were 30,906 
deaths in the HF group over the study period. HF was the primary cause of death in 2,237 
(7.2%) people but listed as any cause in 13,093 (42.4%) cases. HF was also a primary cause 
of death in 1.3% of the no HF group. The second commonest cause of death for people with 
HF was respiratory disease (15.9%) followed by cancer (12.5%). 
 
Table 2: Cause of death in people with heart failure and age, sex and practice matched 
comparators without heart failure 
 Heart Failure  No Heart Failure 
Cause of death subgroup n %  n % 
 
Diseases of the circulatory system 
17,20
7 
(55.7
) 
 24,96
5 (32.7) 
  Heart failure primary cause 2,237 (7.2)  960 (1.3) 
 
 Heart failure any cause of death* 
13,09
3 
(42.4
) 
 
5,528 (7.2) 
  Arrhythmias (ICD-10 codes: I47-I49) 513 (1.7)  684 (0.89) 
 
Diseases of the respiratory system 4,925 
(15.9
) 
 12,22
3 (16.0) 
 
Neoplasms 3,854 
(12.5
) 
 19,88
7 (26.0) 
 Diseases of the digestive system 1,095 (3.5)  3,526 (4.6) 
 Diseases of the genitourinary system 774 (2.5)  1,877 (2.5) 
 Endocrine, nutritional and metabolic diseases 611 (2.0)  876 (1.2) 
 Mental and behavioural disorders 484 (1.6)  4,357 (5.7) 
 External causes of morbidity and mortality 438 (1.4)  1,752 (2.3) 
 Symptoms, signs and abnormal clinical and laboratory 
findings, not elsewhere classified 372 (1.2) 
 
2,263 (3.0) 
 Certain infectious and parasitic diseases 331 (1.1)  873 (1.1) 
 Diseases of the nervous system 318 (1.0)  2,635 (3.5) 
 
Diseases of the musculoskeletal system and connective tissue 219 
(0.71
) 
 
689 (0.9) 
 Diseases of the skin and subcutaneous tissue 174 (0.6)  307 (0.4) 
 Diseases of the blood and blood-forming organs 63 (0.2)  144 (0.2) 
 Congenital malformations, deformations and chromosomal 
abnormalities 36 (0.1) 
 
44 (0.1) 
 Other 5 (0.0)  19 (0.0) 
* Includes patients for whom heart failure may have been the primary, or a contributory cause of death. 
 
Survival in the heart failure group 
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Survival rates in the HF group were 75.9% (95%CI 75·5 to 76.3) at 1 year, 45.5% (95%CI 45.1 
to 46.0) at 5 years, 24.5% (95%CI 23.9 to 25.0) at 10 years, and 12.7% (95%CI 11.9 to 13.5) at 
15 years. Survival rates by age and sex are shown in Table 3. Women had worse short- and 
long-term outcomes; one-year survival 74.5% vs 77.2% (p<0.0001) and 15-year survival 
11.0% vs 14.1% (p<0.0001) for women and men respectively. Age at diagnosis was a 
significant determinant of subsequent survival.  
 
Table 3: One five, ten and fifteen-year survival rates (in %) following a diagnosis of heart 
failure overall and by sex and ten-year age band 
Subgroup 
1-year survival 
% (95%CI) 
5-year survival 
% (95%CI) 
10-year survival 
% (95%CI) 
15-year 
survival 
% (95%CI) 
Overall 
 
75.9  
(75.5 to 76.3) 
45.5  
(45.1 to 46.0) 
24.5  
(23.9 to 25.0) 
12.7  
(11.9 to 13.5) 
Sex     
 
Male 
 
77.2  
(76.7 to 77.7) 
46.9  
(46.3 to 47.6) 
25.8  
(25.0 to 26.5) 
14.1  
(13.1 to 15.2) 
 
Female 
 
74.5  
(74.0 to 75.0) 
44.0  
(43.3 to 44.7) 
23.0  
(22.2 to 23.8) 
11.0  
(9.9 to 12.2) 
Age category (years)     
 
45-54 
 
90.3  
(89.0 to 91.7) 
78.5  
(76.4 to 80.6) 
64.7  
(61.6 to 68.0) 
54.4  
(50.0 to 59.3) 
 
55-64 
 
87.9  
(87.0 to 88.8) 
70.6  
(69.3 to 72.0) 
52.8  
(50.9 to 54.7) 
38.4  
(35.6 to 41.5) 
 
65-74 
 
83.5  
(82.8 to 84.1) 
59.1  
(58.1 to 60.1) 
35.4  
(34.2 to 36.6) 
17.2  
(15.5 to 19.2) 
 
75-84 
 
76.5  
(76.0 to 77.1) 
43.2  
(42.4 to 44.0) 
18.4  
(17.6 to 19.2) 
5.8  
(4.9 to 7.0) 
 
85-94 
 
63.2  
(62.4 to 64.1) 
22.3  
(21.4 to 23.2) 
4.4  
(3.8 to 5.2) 
0.2  
(0.04 to 1.4) 
 
94+ 
 
43.9  
(41.0 to 47.1) 
6.0  
(4.4 to 8.3)   
 
Trends in survival over time 
Overall one-year survival improved by 6.6% (95%CI 4.0 to 9.2) over time for people with a 
new diagnosis of HF from 74.2% (95%CI 72.8 to 75.6) in 2000 to 80.8% (95%CI 78.6 to 83.1) 
in 2016 (Figure 1). Five-year survival improved by 7.2% (95%CI 4.2 to 10.2) from 41.0% 
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(95%CI 39.4 to 42.7) in 2000 to 48.2% (95%CI 45.7 to 50.7) in 2012. Ten-year survival 
improved by 6.3% (95% CI 3.6 to 9.1) from 19.8% (95%CI 18.4 to 21.3) in 2000 to 26.2% 
(95%CI 24.0 to 28.6) in 2007. All trends remained when survival rates were standardised by 
age and sex, and across age groups.  
Survival in patients admitted to hospital at time of diagnosis 
Survival of people with HF hospitalised around the time of diagnosis was significantly worse 
than those not requiring hospitalisation (Figure 2) with a median difference of 2.4 years (5.3 
vs 2.9 years, log rank test, p<0.0001). One-year survival was 81.2% vs 68.8%, five-year 
survival 51.8% vs 36.7%, 10-year survival 28.8% vs 17.8% and 15-year survival 15.5% vs 8.1% 
for the non-hospitalised and hospitalised groups respectively. Survival rates by year of 
diagnosis improved more rapidly for people diagnosed and managed in the community 
(Figure 3a) than for people requiring hospital admission at the time of diagnosis (Figure 3b). 
Socioeconomic inequalities 
In the HF group, there were 10,854 people in the least and 8,447 in the most deprived 
quintile. Overall, there was a deprivation gap of 2.4 years in median survival between least 
and most deprived (11.1 vs 8.7 years, p<0.0001). The trends in survival over time by 
deprivation quintile are shown in Figure 4. There was little difference between one and five-
year survival in the most deprived and most affluent quintiles over the study period, but 
ten-year survival was lower in the most deprived group from 2000 to 2006 although this gap 
improved in 2007. 
Overall survival in the cohort 
The median survival time for those with HF was 18 months compared to 36 months for 
those without HF. Cox regression analysis suggested that, overall people with HF had a 
significantly worse prognosis than their age, sex, ethnicity and practice matched 
comparators as shown in Figure 5 (Hazard ratio (HR)=3.36 (95%CI 3.31 to 3.42)). An 
increased risk of death remained for those with HF after adjustment for deprivation, 
ethnicity and CV risk factors (HR=3.05 (95%CI 3.00- 3.11)). Similar results were observed in 
the sensitivity analysis of the fully adjusted model (HR=3.17 (95%CI 3.09 to 3.26), from 
complete case analysis in 186,285 patients and in the adjusted model where cholesterol and 
BMI were excluded (HR=30.2 (95%CI 2.96 to 3.08) with 280,211 patients). 
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Discussion 
This large community-based study provides contemporary survival estimates for people 
with a new diagnosis of HF across an 18-year period. People admitted to hospital around the 
time of diagnosis had worse survival than those diagnosed and managed in primary care. 
Survival following HF diagnosis gradually improved over time but more rapidly in the 
primary care group. The deprivation gap in survival of 2.4 years between the least and most 
deprived quintiles suggests socioeconomic inequalities in HF care. 
A total of 55,959 people with a new diagnosis of HF from the millennium to the end of 2017 
were included allowing reliable analyses of subgroups (year of diagnosis, hospitalisation, 
socioeconomic quintile) and recent survival trends. The data were taken directly from 
primary and secondary care sources with linkage between databases. ONS mortality data is 
determined by the information provided on the death certificate by the doctor involved in 
caring for the patient around the time of death. There is known variation in death recording 
in general practice so, whilst death certification which may be inaccurate in some cases, 
ONS data is likely to be the most reliable available. 
In the UK, healthcare is provided to the entire population, through registration with a 
primary care provider, and routinely collected data is being increasingly used to explore 
epidemiological trends.24,25 However, the main reason for primary care physicians to code 
medical information is to enable clinical care, rather than for research purposes, and this 
can potentially lead to incomplete data. However, previous studies have shown that there is 
good recording of diagnoses in this database and of HF in healthcare databases more 
generally. We also sought to confirm primary care diagnoses using hospital data and any 
under-reporting of heart failure would have diluted the observed association between heart 
failure and mortality, so we are confident that our overall findings are robust. 
Practices using the Vision clinical system provide data directly to CPRD. In the last few years, 
CPRD has seen a reduction in the number of practices contributing data due to a decline in 
the popularity of Vision software. There is a move to link with alternative clinical system 
providers to maintain the large dataset. Despite the lower number of practices towards the 
end of the study period, and observing a moderate level of unrecorded data, our sensitivity 
analysis suggests our conclusions are robust.  
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We acknowledge there may be some misclassification of people with pre-existing HF as 
being new cases of HF or having no HF, however, this is likely to be minimised by the linkage 
of electronic data from CPRD, HES and ONS mortality data. Evidence of close agreement 
between HF incidence in CPRD with population surveillance studies has also been found. It 
was also not possible to identify the type of HF (reduced or preserved ejection fraction) in 
this study which would have been desirable given the differences in management 
depending on ejection fraction. We hope this will be possible in the future as 
echocardiography coding becomes more sophisticated and codes for HF with preserved 
ejection are increasingly used. 
HF was listed as a cause of death in less than half of people with HF. Other cardiovascular 
diseases, respiratory disorders and cancer were also common causes of death in people 
with a HF diagnosis. People with HF are often living with several long-term conditions; a 
large study using UK data found 79% of people with HF had three or more comorbidities.4 
Cardiovascular diseases, particularly AF, diabetes, ischaemic heart disease, and stroke, were 
the most common co-existing conditions. Other diseases including cancer (25%), chronic 
kidney disease (24%) and depression (22%) were prevalent and co-morbidities occurred at a 
younger age in deprived populations with HF. In the no HF group, 1.3% of people had HF as 
a primary cause of death. This is likely to be people who developed acute HF and died soon 
afterwards so did not have a diagnosis in their primary care record. In the most recent 
National Heart Failure audit, in-hospital mortality was 9.4%. 
The presence of multimorbidity (two or more long-term conditions) can make the diagnosis 
of HF difficult, as symptoms overlap, and management more challenging. Two third of 
people with HF have three or more other long-term conditions and the average age of 
diagnosis in primary care in our study was 77 years old. Survival following a diagnosis of HF 
is therefore unlikely to be dependent on HF care alone. Holistic, person-centred care is 
required to optimally manage people with HF in the context of multimorbidity with a focus 
on quality of life, as well as length of survival. 
Our study also did not explore the impact of drugs, devices of transplantation on the 
survival of people with HF. Our aim for this study was to present contemporary short, mid 
and long-term survival rates at a population level, and explore trends over time. Further 
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work to explore the impact of new treatments, technologies, guidelines and health policies 
is also needed to understand their impact at patient-level. 
There is considerable variation in previous HF survival estimates depending on the study 
setting. People with acute HF recruited from hospital inpatient populations have 
comparatively poor outcomes. Amongst 12,440 people with HF in the European Society of 
Cardiology Heart Failure Long-Term registry, one-year mortality was 23.6% and 6.4% for 
people with acute and chronic HF respectively across Europe.26 Despite initiatives in many 
countries to improve care for people with HF, success has been limited. The most recent 
annual National Heart Failure Audit in England reported one-year mortality rates of 29.6% 
amongst people admitted with HF and this had not improved for the previous six years 
despite service restructuring to provide patients with input from specialist HF teams during 
admission and immediately post-discharge.27  
Population-based studies, such as Framingham or the Echocardiographic Heart of England 
Screening (ECHOES) study, have reported long-term survival for people with HF but 
participants were invited for screening rather than presenting to primary care with 
symptoms.10,28 In the ECHOES cohort, five- and ten-year survival rates of people with HF 
were 53% and 27% but diagnosis at screening is likely to represent an earlier disease stage.28 
Several European countries have established registries using routinely collected healthcare 
data to monitor trends in long term conditions. In Sweden, amongst 88,038 people with HF, 
overall five-year survival was 48% and survival rates improved by 19% between 2006 and 
2010.13 
Our previous study exploring survival rates in The Health Improvement Network (THIN) 
database, without HES or IMD linkage, between 1998 and 2012 found no improvement in 
survival over that time period. This conclusion was alarming to the HF community, and we 
wanted to conduct further analysis in a different dataset with linkage to hospital and 
deprivation data to verify and explore the findings further. In this CPRD study we have 
provided contemporary survival rates up to 2017 which have shown a modest improvement 
in survival since the millennium. We have also been able to go further, comparing survival 
related to hospitalisation around the time of diagnosis and between socioeconomic groups. 
This analysis has highlighted the importance to timely diagnosis in primary care and the gap 
in survival between the most and least deprived individuals. 
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The gradual improvements in survival rates over time found in our study are encouraging 
but outlook following a new diagnosis of HF remains poor compared to other malignant 
conditions such as cancer where overall survival has doubled in the last 40 years.29 Hospital 
admission at the time of HF diagnosis is likely to be related to a more advanced stage of 
disease. Earlier diagnosis in primary care may allow treatment initiation and avoid 
emergency admission. 
HF has not been a priority area in government policy or funding and has been described as 
the ‘Cinderella Syndrome’. However, in 2006 a HF indicator was introduced to the Quality 
and Outcomes Framework (QOF) for GPs in England. The indicator aimed to incentivise GPs 
to use echocardiography to support diagnosis and initiation of angiotensin converting 
enzyme inhibitors and beta-blockers for people with an ejection fraction below 40%. It is not 
possible to establish the direct impact of the QOF indicator from our data but the 10-year 
survival difference, observed in previous years, between the least and most deprived groups 
became non-significant in 2007.  
There has been a sustained improvement in cancer survival rates following the introduction 
of the Cancer Plan in 2000 which included both investment and infrastructure changes to 
improve diagnosis and treatment.30 The lack of substantial progress in improving HF survival 
rates should alert policymakers to the need for further investment in HF services. Improved 
GP access to diagnostics such as natriuretic peptide testing, rapid referral pathways (like the 
‘two week wait cancer’ pathways) for echocardiography and specialist assessment and early 
treatment initiation may be areas for improvement. Primary care-led research is also 
needed to understand the complexity of HF diagnosis and management in the community 
and to develop and test new strategies to achieve better outcomes for patients. 
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What is already known on this topic 
Heart failure is an increasingly prevalent condition affecting over 920,000 people in the UK. 
Survival for people with established heart failure is poor. Studies exploring survival trends 
over time are inconsistent. 
What this study adds 
This study provides short and long-term survival rate estimates for people with a new 
diagnosis of heart failure in primary care. Improvement in survival since the millennium has 
been modest and socioeconomic inequalities persist. People not requiring hospitalisation 
around the time of diagnosis lived longer which is likely to reflect detection at an earlier 
stage of disease. 
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